Advertisement

Human Trichomoniasis

  • Sumeeta Khurana
  • Shreya Singh
Chapter

Abstract

Human trichomoniasis is a sexually transmitted disease of global concern with millions of cases reported worldwide. The causative agent is Trichomonas vaginalis, a flagellated protozoan, which primarily resides in the genitourinary tract of affected women and men. Apart from causing discomfort due to malodourous discharge, vaginal irritation, and dysuria, it can also cause complications such as infections of the adjoining glands and endometrium, premature labor in pregnant women, and even cervical dysplasia. The diagnosis can be made on clinical examination, wet mount microscopy, stained smear examination, and antigen detection using commercial kits. Rapid nucleic acid amplification-based platforms are also available which demonstrate high sensitivity and specificity for detection of T. vaginalis. The management primarily consists of administration of 2 g of a single dose of oral metronidazole or tinidazole, with concomitant treatment of the sexual partner. Prevention of infection in high-risk individuals can be ensured by using condoms, microbicidal vaginal suppositories, and hydrogels containing antimicrobial peptides. Vaccination has shown promise in animal trichomoniasis; however, identification of candidates for human use and subsequent development of vaccines for humans are still in the pipeline.

Keywords

Hydrogels Microbicidal vaginal suppositories Sexually transmitted disease Trichomoniasis Trichomonas vaginalis 

References

  1. Afzan MY, Suresh K (2012) Pseudocyst forms of Trichomonas vaginalis from cervical neoplasia. Available from: http://repository.um.edu.my/29663/1/AfzanandSuresh.pdf
  2. Anjaeyulu R, Gupte SA, Desai DB (1977) Single-dose treatment of trichomonal vaginitis: a comparison of tinidazole and metronidazole. J Int Med Res 5:438–441 Available from: http://www.ncbi.nlm.nih.gov/pubmed/590601 PubMedGoogle Scholar
  3. Arora BB, Maheshwari M, Devgan N, Arora DR (2014) Prevalence of trichomoniasis, vaginal candidiasis, genital herpes, chlamydiasis, and actinomycosis among urban and rural women of Haryana. Indian J Sex Transm Dis 29:1–5 Available from: http://www.hindawi.com/journals/jstd/2014/963812/ CrossRefGoogle Scholar
  4. Badman SG, Causer LM, Guy R, Tabrizi SN, Francis F, Donovan B et al (2016) A preliminary evaluation of a new GeneXpert (Gx) molecular point-of-care test for the detection of Trichomonas vaginalis. Sex Transm Infect 92:350–352 Available from: http://sti.bmj.com/lookup/doi/10.1136/sextrans-2015-052384 CrossRefGoogle Scholar
  5. Bouchemal K, Bories C, Loiseau PM (2017) Strategies for prevention and treatment of Trichomonas vaginalis infections. Clin Microbiol Rev 30:811–825 Available from: http://www.ncbi.nlm.nih.gov/pubmed/28539504 CrossRefGoogle Scholar
  6. Bowden FJ, Garnett GP (2000) Trichomonas vaginalis epidemiology: parameterising and analysing a model of treatment interventions. Sex Transm Infect 76:248–256 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11026878 CrossRefGoogle Scholar
  7. Burch TA, Rees CW, Reardon L (1959) Diagnosis of Trichomonas vaginalis vaginitis. Am J Obstet Gynaecol 77:309–313.  https://doi.org/10.1016/0002-9378(59)90232-7 CrossRefGoogle Scholar
  8. Centres for Disease Control and Prevention (CDC). Trichomoniasis-2015 (2017) STD treatment guidelines [internet]. [Cited 2017, July 12]. Available from: https://www.cdc.gov/std/tg2015/trichomoniasis.htm
  9. Chapin K, Andrea S (2011) APTIMA Trichomonas vaginalis, a transcription-mediated amplification assay for detection of Trichomonas vaginalis in urogenital specimens. Expert Rev Mol Diagn 11:679–688 Available from: http://www.tandfonline.com/doi/full/10.1586/erm.11.53 CrossRefGoogle Scholar
  10. Crucitti T, Jespers V, Mulenga C, Khondowe S, Vandepitte J, Buvé A (2011) Non-sexual transmission of Trichomonas vaginalis in adolescent girls attending school in Ndola, Zambia. PLoS One 6:e16310 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21305023 CrossRefGoogle Scholar
  11. Cudmore SL, Garber GE (2010) Prevention or treatment: the benefits of Trichomonas vaginalis vaccine. J Infect Public Health 3:47–53 Available from: http://www.ncbi.nlm.nih.gov/pubmed/20701891 CrossRefGoogle Scholar
  12. Das A, Prabhakar P, Narayanan P, Neilsen G, Wi T, Kumta S et al (2011) Prevalence and assessment of clinical management of sexually transmitted infections among female sex workers in two cities of India. Infect Dis Obstet Gynaecol 2011:494769 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21747642 Google Scholar
  13. Deivam S, Rajalakshmi R, Priyadharshini S, Seethalaksmi R, Balasubramanian N, Brinda T et al (2017) Prevalence of Trichomonas vaginalis infection among patients that presented to Rural Tertiary Care Hospital in Tiruchirapalli, India in 2011 and 2013, vol 2, pp 255–260. Available from: http://www.pharmahealthsciences.net/pdfs/urgent/10_MS_1466.pdf
  14. Dickinson B (2017) BD affirm™ VPIII microbial identification system [internet]. [Cited Jul 13]. Available from: http://moleculardiagnostics.bd.com/product/affirm/
  15. Fule R, Fule S, Tankhiwale N (2012) Clinical and laboratory evidence of Trichomonas vaginalis infection among women of reproductive age in rural area. Indian J Med Microbiol 30:314 Available from: http://www.ijmm.org/text.asp?2012/30/3/314/99493 CrossRefGoogle Scholar
  16. Garber GE (2005) The laboratory diagnosis of Trichomonas vaginalis. Can J Infect Dis Med Microbiol 16:35–38 Available from: http://www.ncbi.nlm.nih.gov/pubmed/18159526 CrossRefGoogle Scholar
  17. Gaydos CA, Klausner JD, Pai NP, Kelly H, Coltart C, Peeling RW (2017) Rapid and point-of-care tests for the diagnosis of Trichomonas vaginalis in women and men. Sex Transm Infect 93:S31–S35 [Internet]. Jul 6 [cited 2017 Jul 21];sextrans-2016-053063. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28684611 CrossRefGoogle Scholar
  18. Global-Disease-Burden (2017) Trichomoniasis in India – statistics, demographics affected [internet]. [Cited 2017 Jul 13]. Available from: http://global-disease-burden.healthgrove.com/l/25879/Trichomoniasis-in-India
  19. Hosny AE-DMS, El-Khayat W, Kashef MT, Fakhry MN (2017) Association between preterm labour and genitourinary tract infections caused by Trichomonas vaginalis, Mycoplasma hominis, gram-negative bacilli, and coryneforms. J Chin Med Assoc 80:575–581 Available from: http://www.ncbi.nlm.nih.gov/pubmed/28094234 CrossRefGoogle Scholar
  20. Johnston VJ, Mabey DC (2008) Global epidemiology and control of Trichomonas vaginalis. Curr Opin Infect Dis 21:56–64 Available from: http://www.ncbi.nlm.nih.gov/pubmed/18192787 CrossRefGoogle Scholar
  21. Kaydos-Daniels SC, Miller WC, Hoffman I, Banda T, Dzinyemba W, Martinson F et al (2003) Validation of a urine-based PCR-enzyme-linked immunosorbent assay for use in clinical research settings to detect Trichomonas vaginalis in men. J Clin Microbiol 41:318–323 Available from: http://www.ncbi.nlm.nih.gov/pubmed/12517867 CrossRefGoogle Scholar
  22. Kissinger P (2015) Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues. BMC Infect Dis 15:307 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26242185 CrossRefGoogle Scholar
  23. Kissinger P, Mena L, Levison J, Clark RA, Gatski M, Henderson H et al (2010) A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr 55:565–571 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21423852 CrossRefGoogle Scholar
  24. Klausner JD, Broutet N (2017) Health systems and the new strategy against sexually transmitted infections. Lancet Infect Dis 3099:9–10 Available from: http://linkinghub.elsevier.com/retrieve/pii/S1473309917303614 Google Scholar
  25. Lawing LF, Hedges SR, Schwebke JR (2000) Detection of trichomonosis in vaginal and urine specimens from women by culture and PCR. J Clin Microbiol 38:3585–3588 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11015368 PubMedPubMedCentralGoogle Scholar
  26. Madhivanan P, Bartman MT, Pasutti L, Krupp K, Arun A, Reingold AL et al (2009) Prevalence of Trichomonas vaginalis infection among young reproductive age women in India: implications for treatment and prevention. Sex Health 6:339–344 Available from: http://www.ncbi.nlm.nih.gov/pubmed/19917204 CrossRefGoogle Scholar
  27. Malla N, Kaur S, Khurana S, Bagga R, Wanchu A (2008) Trichomoniasis among women in North India: a hospital based study. Indian J Sex Transm Dis AIDS 29:76 Available from: http://www.ijstd.org/text.asp?2008/29/2/76/48729 CrossRefGoogle Scholar
  28. Mann JR, McDermott S, Zhou L, Barnes TL, Hardin J (2009) Treatment of trichomoniasis in pregnancy and preterm birth: an observational study. J Women’s Health 18:493–497 Available from: http://www.ncbi.nlm.nih.gov/pubmed/19361316 CrossRefGoogle Scholar
  29. Marous M, Huang W-Y, Rabkin CS, Hayes RB, Alderete JF, Rosner B et al (2017) Trichomonas vaginalis infection and risk of prostate cancer: associations by disease aggressiveness and race/ethnicity in the PLCO trial. Cancer Causes Control 28:889–898 Available from: http://www.ncbi.nlm.nih.gov/pubmed/28669054 CrossRefGoogle Scholar
  30. Meites E, Gaydos CA, Hobbs MM, Kissinger P, Nyirjesy P, Schwebke JR et al (2015) A review of evidence-based care of symptomatic trichomoniasis and asymptomatic Trichomonas vaginalis infections. Clin Infect Dis 61(Suppl. 8):S837–S848 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26602621 CrossRefGoogle Scholar
  31. Moodley P, Wilkinson D, Connolly C, Moodley J, Sturm AW (2002) Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis 34:519–522 Available from: http://www.ncbi.nlm.nih.gov/pubmed/11797180 CrossRefGoogle Scholar
  32. Muthusamy S, Elangovan S (2017) A study on the prevalence of genital trichomoniasis among female outpatients attending sexually transmitted infection clinic in a tertiary care hospital. J Lab Phys 9:16–19 Available from: http://www.ncbi.nlm.nih.gov/pubmed/28042211 Google Scholar
  33. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N et al. 2015. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting (Meng Z (ed)). PLoS One 10:e0143304. Available from: http://dx.plos.org/10.1371/journal.pone.0143304
  34. O-Prasertsawat P, Jetsawangsri T (1992) Split-dose metronidazole or single-dose tinidazole for the treatment of vaginal trichomoniasis. Sex Transm Dis 19:295–297 Available from: http://www.ncbi.nlm.nih.gov/pubmed/1411848 CrossRefGoogle Scholar
  35. Pattullo L, Griffeth S, Ding L, Mortensen J, Reed J, Kahn J et al (2009) Stepwise diagnosis of Trichomonas vaginalis infection in adolescent women. J Clin Microbiol 47:59–63 Available from: http://www.ncbi.nlm.nih.gov/pubmed/18987174 CrossRefGoogle Scholar
  36. Pereira-Neves A, Ribeiro KC, Benchimol M (2003) Pseudocysts in trichomonads – new insights. Protist 154:313–329 Available from: http://www.ncbi.nlm.nih.gov/pubmed/14658492 CrossRefGoogle Scholar
  37. Pillay A, Lewis J, Ballard RC (2004) Evaluation of Xenostrip-Tv, a rapid diagnostic test for Trichomonas vaginalis infection. J Clin Microbiol 42:3853–3856 Available from: http://www.ncbi.nlm.nih.gov/pubmed/15297548 CrossRefGoogle Scholar
  38. Schwebke JR, Barrientes FJ (2006) Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother 50:4209–4210 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17000740 CrossRefGoogle Scholar
  39. Schwebke JR, Burgess D (2004) Trichomoniasis. Clin Microbiol Rev 17:794–803 Available from: http://cmr.asm.org/content/17/4/794.short CrossRefGoogle Scholar
  40. Schwebke JR, Lensing SY, Sobel J (2013) Intravaginal metronidazole/miconazole for the treatment of vaginal trichomoniasis. Sex Transm Dis 40:710–714 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23949586 CrossRefGoogle Scholar
  41. Shui IM, Kolb S, Hanson C, Sutcliffe S, Rider JR, Stanford JL (2016) Trichomonas vaginalis infection and risk of advanced prostate cancer. Prostate 76:620–623 Available from: https://insights.ovid.com/pubmed?pmid=26818005 CrossRefGoogle Scholar
  42. Smith J, Garber GE (2014) Current status and prospects for development of a vaccine against Trichomonas vaginalis infections. Vaccine 32:1588–1594 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23916988 CrossRefGoogle Scholar
  43. Sonkar S, Yadav S, Malla N, Dhanda R, Khurana S, Bagga R et al (2016) Evaluation of DNA based techniques for the diagnosis of human vaginal trichomoniasis in North Indian population. Br Microbiol Res J 17:1–12 Available from: http://www.sciencedomain.org/abstract/17070 CrossRefGoogle Scholar
  44. Stringer E, Read JS, Hoffman I, Valentine M, Aboud S, Goldenberg RL (2010) Treatment of trichomoniasis in pregnancy in sub-Saharan Africa does not appear to be associated with low birth weight or preterm birth. S Afr Med J 100:58–64 Available from: https://pdfs.semanticscholar.org/4c44/f28a3a94532bca269390b3aa5a9c6ea4450e.pdf PubMedPubMedCentralGoogle Scholar
  45. Swygard H, Seña AC, Hobbs MM, Cohen MS (2004) Trichomoniasis: clinical manifestations. Diagn Manag Sex Transm Infect 80:91–95 Available from: http://sti.bmj.com/content/sextrans/80/2/91.full.pdf CrossRefGoogle Scholar
  46. Tayal SC, Ochogwu SA, Bunce H (2010) Paromomycin treatment of recalcitrant Trichomonas vaginalis. Int J STD AIDS 21:217–218 Available from: http://www.ncbi.nlm.nih.gov/pubmed/20215633 CrossRefGoogle Scholar
  47. Wang P-J, Xie C-B (2012) Mycoplasma hominis symbiosis and Trichomonas vaginalis metronidazole resistance. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 30:210–213 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23072138 PubMedGoogle Scholar
  48. Wiese W, Patel SR, Patel SC, Ohl CA, Estrada CA (2000) A meta-analysis of the Papanicolaou smear and wet mount for the diagnosis of vaginal trichomoniasis. Am J Med 108:301–308 Available from: http://linkinghub.elsevier.com/retrieve/pii/S0002934399004660 CrossRefGoogle Scholar
  49. World Health Organization (2008) Global incidence and prevalence of selected curable sexually transmitted infections – 2008. WHO. [Internet]. [cited 2017 Jul 10]. Available from: http://www.who.int/reproductivehealth/publications/rtis/stisestimates/en/

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Sumeeta Khurana
    • 1
  • Shreya Singh
    • 1
  1. 1.Department of Medical ParasitologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations